Inovio Pharmaceuticals CMV Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study

News   Nov 28, 2012

 
Inovio Pharmaceuticals CMV Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
 
 
 

RELATED ARTICLES

BC Platforms Announces Collaborations in Multiple Sclerosis Research

News

Company's technology and research platforms used to better understand genetic basis of MS.

READ MORE

Biomedical Catalyst Award Goes To BioMoti, Pharmidex and Queen Mary University of London

News

The grant was awarded under the Biomedical Catalyst funding competition to support preclinical studies of new therapeutic approaches for hard-to-treat tumours including advanced ovarian, triple negative breast and pancreatic cancers.

READ MORE

A New Tactic in the Fight Against Drug-Resistant Infections

News

$1 million research grant could lead to life-saving antibiotics.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE